z-logo
open-access-imgOpen Access
Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling
Author(s) -
Connor A. Emdin,
Amit V. Khera,
Derek Klarin,
Pradeep Natarajan,
Seyedeh M. Zekavat,
Akihiro Nomura,
Mary E. Haas,
Krishna G. Aragam,
Diego Ardissino,
James G. Wilson,
Heribert Schunkert,
Ruth McPherson,
Hugh Watkins,
Roberto Elosúa,
Matthew J. Bown,
Nilesh J. Samani,
Usman Baber,
Jeanette Erdmann,
Padhraig Gormley,
Aarno Palotie,
Nathan O. Stitziel,
Namrata Gupta,
John Danesh,
Danish Saleheen,
Stacey Gabriel,
Sekar Kathiresan
Publication year - 2017
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.117.028021
Subject(s) - medicine , phenotype , nitric oxide , genetic predisposition , genetics , pathology , biology , disease , gene
Background: Nitric oxide signaling plays a key role in the regulation of vascular tone and platelet activation. Here, we seek to understand the impact of a genetic predisposition to enhanced nitric oxide signaling on risk for cardiovascular diseases, thus informing the potential utility of pharmacological stimulation of the nitric oxide pathway as a therapeutic strategy. Methods: We analyzed the association of common and rare genetic variants in 2 genes that mediate nitric oxide signaling (Nitric Oxide Synthase 3 [NOS3 ] and Guanylate Cyclase 1, Soluble, Alpha 3 [GUCY1A3 ]) with a range of human phenotypes. We selected 2 common variants (rs3918226 inNOS3 and rs7692387 inGUCY1A3 ) known to associate with increasedNOS3 andGUCY1A3 expression and reduced mean arterial pressure, combined them into a genetic score, and standardized this exposure to a 5 mm Hg reduction in mean arterial pressure. Using individual-level data from 335 464 participants in the UK Biobank and summary association results from 7 large-scale genome-wide association studies, we examined the effect of this nitric oxide signaling score on cardiometabolic and other diseases. We also examined whether rare loss-of-function mutations inNOS3 andGUCY1A3 were associated with coronary heart disease using gene sequencing data from the Myocardial Infarction Genetics Consortium (n=27 815).Results: A genetic predisposition to enhanced nitric oxide signaling was associated with reduced risks of coronary heart disease (odds ratio, 0.37; 95% confidence interval [CI], 0.31-0.45;P =5.5*10–26 ], peripheral arterial disease (odds ratio 0.42; 95% CI, 0.26-0.68;P =0.0005), and stroke (odds ratio, 0.53; 95% CI, 0.37-0.76;P =0.0006). In a mediation analysis, the effect of the genetic score on decreased coronary heart disease risk extended beyond its effect on blood pressure. Conversely, rare variants that inactivate theNOS3 orGUCY1A3 genes were associated with a 23 mm Hg higher systolic blood pressure (95% CI, 12-34;P =5.6*10–5 ) and a 3-fold higher risk of coronary heart disease (odds ratio, 3.03; 95% CI, 1.29-7.12;P =0.01).Conclusions: A genetic predisposition to enhanced nitric oxide signaling is associated with reduced risks of coronary heart disease, peripheral arterial disease, and stroke. Pharmacological stimulation of nitric oxide signaling may prove useful in the prevention or treatment of cardiovascular disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom